Rafa Laboratories
Company
Rafa Laboratories develops one asset, approved (nogapendekin alfa inbakicept-pmln in bcg-unresponsive non-muscle invasive bladder cancer). Mostly protein or enzyme acting on IL2RB, IL2RG and IL15RA.
- 1
- Asset
- Furthest stage
- Approved
- 3
- Trials
- 3
- Signals
Pipeline
1nogapendekin alfa inbakicept-pmln
IL-15 superagonist enhances natural killer and T-cell responses to support vaccine-mediated cancer prevention.
Approved, Protein or enzyme, IL2RB, IL2RG, bcg-unresponsive non-muscle invasive bladder cancer, bladder cancer, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials3
- Signals11
- Similar companies6